Corporate Overview

The Jenex Corporation is a publicly traded company (NEX : JEN.H) focused on servicing the $21 billion cosmeceutical industry.  The Company holds the patents, trademarks and regulatory approvals for its breakthrough thermal therapy technology that uses heat and light energy to deliver effective, non-invasive and pain free skin care.

With over $6.5 million invested in intellectual property and research and development, Jenex's current product line addresses cold sores treatment and prevention, and anti-bug bite treatment.

The Company's current focus is re-establishing its relationships with major North American retailers and pursuing the redesign of Jenex's existing platforms and commercializing new technologies.


The skincare market is undergoing rapid growth fueled by an aging population, advances in skin care, and the convergence of pharmaceutical and cosmetics products - “cosmeceuticals”. Like cosmetics, cosmeceuticals are topically applied, but they contain ingredients that influence the biological function of the skin. Dermatological research suggests that the bioactive ingredients used in cosmeceuticals have benefits beyond the traditional cosmetics and thus provide protection, prevention and regeneration that surpass traditional cosmetics. 

Today, as the demand increases for effective skin care treatments, consumers continue to educate themselves in the selection of home care products and alternatives to expensive procedures.  Products that help people feel better and provide actual skin repair from the comfort of their home are expected to become the focus of the anti-aging skincare industry.

Jenex occupies a unique market position. Its products tap into this new approach to skin care, combining clinically proven and scientifically endorsed technology with a cost-effective and efficient delivery method to treat a variety of skin conditions.

Market Summary

According to various studies, the skin care device market is expected to reach USD 10.7 Billion by 2018.

Current medical research indicates that 20 to 40% of the population experience recurrent cold sore outbreaks.  In the Canadian market alone, that figure translates from 5 million to as many as 10 million people who suffer recurrent bouts of cold sores.  In the United States these estimates translate to between 40-80 million recurrent cold sore sufferers.